These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38364830)

  • 1. ELEVATEd hope for patients after migraine treatment failure.
    Xu X; Dong L; Zhou J
    Lancet Neurol; 2024 Apr; 23(4):328-330. PubMed ID: 38364830
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic Cannabis Use and Treatment Failure of Onabotulinum Toxin A for Chronic Migraine.
    Chan TLH; Zhang N
    Can J Neurol Sci; 2019 Nov; 46(6):785-786. PubMed ID: 31469061
    [No Abstract]   [Full Text] [Related]  

  • 3. Botox therapy for refractory chronic migraine.
    Conway S; Delplanche C; Crowder J; Rothrock J
    Headache; 2005 Apr; 45(4):355-7. PubMed ID: 15836573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind controlled study of nifedipine as an abortive treatment in acute attacks of migraine with aura.
    Hoffert MJ; Scholz MJ; Kanter R
    Cephalalgia; 1992 Oct; 12(5):323-4. PubMed ID: 1423566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botox, migraine, and the American Academy of Neurology: an antidote to anecdote.
    Jackson M; Barbuto JP
    J Manag Care Pharm; 2008 Jun; 14(5):465-7. PubMed ID: 18597576
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal Antibody Overcomes Migraine Treatment Failure.
    Slomski A
    JAMA; 2022 Aug; 328(8):700. PubMed ID: 35997735
    [No Abstract]   [Full Text] [Related]  

  • 7. Atypical cluster and migraine headache starting with a reverse epicrania fugax.
    Jin P; Wang Y
    Pain Med; 2013 May; 14(5):765-6. PubMed ID: 23565901
    [No Abstract]   [Full Text] [Related]  

  • 8. Migraine-like headache in bacterial meningitis.
    Lampl C; Yazdi K; Buzath A; Klingler D
    Cephalalgia; 2000 Oct; 20(8):738-9. PubMed ID: 11167904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.
    Absher JR
    Ann Intern Med; 2022 Oct; 175(10):JC117. PubMed ID: 36191321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to 'Do different treatment strategies of galcanezumab have similar effect on migraine?'.
    Goadsby PJ; Terwindt GM; Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK
    Eur J Neurol; 2020 May; 27(5):e25. PubMed ID: 32052515
    [No Abstract]   [Full Text] [Related]  

  • 11. Migraine: Telcagepant provides new hope for people with migraine.
    Edvinsson L
    Nat Rev Neurol; 2009 May; 5(5):240-2. PubMed ID: 19488079
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is menstrually associated migraine difficult to treat?
    Massiou H
    Cephalalgia; 1999 Jul; 19 Suppl 24():13-5; discussion 15-8. PubMed ID: 10526677
    [No Abstract]   [Full Text] [Related]  

  • 14. Do different treatment strategies of galcanezumab have a similar effect on migraine?
    Huang IH; Wu PC; Lee YH; Kang YN
    Eur J Neurol; 2020 Apr; 27(4):e19-e20. PubMed ID: 31846550
    [No Abstract]   [Full Text] [Related]  

  • 15. Refractory migraine in a "just world".
    Jones JM
    Headache; 2015 Jan; 55(1):183-5. PubMed ID: 25385653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study.
    Borhani Haghighi A; Motazedian S; Rezaii R; Mohammadi F; Salarian L; Pourmokhtari M; Khodaei S; Vossoughi M; Miri R
    Int J Clin Pract; 2010 Mar; 64(4):451-6. PubMed ID: 20456191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.
    Nichols R; Doty E; Sacco S; Ruff D; Pearlman E; Aurora SK
    Headache; 2019 Feb; 59(2):192-204. PubMed ID: 30462830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New hope for people with migraine headaches.
    Harv Health Lett; 2014 Jul; 39(9):8. PubMed ID: 25314737
    [No Abstract]   [Full Text] [Related]  

  • 20. CGRP antagonists: hope for a new era in acute migraine treatment.
    Schelstraete C; Paemeleire K
    Acta Neurol Belg; 2009 Dec; 109(4):252-61. PubMed ID: 20120204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.